流感

3

!!

(Seasonal Influenza or Seasonal Flu) H1N1H3N2 A/ B!

)Influenza Season or Flu Season* 7 1 6 30

)Influenza Epidemic Period* 11 3 6 9

(Complicated Influenza ) ()()

(Pneumonia and Influenza, P&I) 1975 (ICD-9) 480-487

(480)(481)(482)(485*(486)(487)

(Cluster) !!!!

3

4

!

2008 2009 H1N1 2011 9 2012 2011 12H5N1 ICRapiacta

2013

4

5

(Description of Disease)

(Influenza )

(Influenza virus) 1 4(1,2)

(1-3) 10

3~7 2(2,3)common cold

(Influenza)

(Common Cold)

200

/ 3-4 1-2 2-5

() ()

5

6

(Reye syndrome)(1-5)

1933Wilson Smith(1-3) A(H1N1) ABC A B A B 1977A(H1N1 H3N2) B

)Orthomyxoviridae)

ABC Segmented RNA 80-120nmenvelope 2 - HemagglutininHA, H NeuraminidaseNA, N (1-5)M1M2A B 8 (-)RNA (-)RNA NucleoproteinNPTranscriptaseRNA PB1PB2PA C 7(1,3,4)

(HA NA) A (H ) (N )

6

7

H 17 H1-H17N 10 N1-N10(1-4,7) HA NA H1N1 A HA-1 NA-1 H3N2 A HA-3 NA-2 B C(1-4)

A B A H1N1H2N2H3N2 H1N1H7N7 H3N8 B BC(1,3,4)

A 1957 1968 ( A/H2N2 A/H3N2)

A B C 8 8 7 11 11 9 (Antigenic

drift) (Antigenic shift)

(Antigenic drift)

(Antigenic drift)

A

7

8

2009 H1N1

1. A B 8 RNA C 7

2. 3.

4. 5. Zanamivir(Relenza ) Oseltamivir(Tamiflu )

6. Reassortment

ABC 1980(WHO) H N (1,6)A (HnNn) A/swine/Lowa/15/33 (H1N1) A1933 Lowa H1N1 15A/Beijing/262/95 (H1N1) A 1995 262Beijing H1HA N1NA(1-4) B /// HA NAB/Beijing/243/97 C(1-4)

8

9

A -(1,3,4) RNA RNA"""# HA NA"Antigenic drift""" A B "Antigenic shift""" 20-30(1,3,4) A

48 60 5 10 (1,3,6)

(NA)SheddingViremia(1-4)

9

10

Mode of transmission!

Incubation period 1~4 2

12 3

Period of communicability 3~5 7-10 (1,2) 24-48 24-72 5 (4,6)(1,2,5) 21

Susceptibility and resistance Antigenic drift(2,5) (2,5)

AB

A C

10

11

Pandemics(Seasonal epidemics)(Sporadic cases*

(WHO) 3 5 25 50(1)(Centers for Disease Control and Prevention, CDC) 10 3 10 4 2~4 5 100(100/100,000) 500/100,000(2,6,8)2012-2013 11 1A/H3N2 (9)11 3 42012-2013 12 2(EuroFlu) 2012-2013 94,000 63% A 2009 A/H1N1( 66%) (9)! Centre for Health Protection 12 7 82012-2013 A/H3N2 2009 A/H1N1(10) 2012-201311 2013 1 2 A/H3N2(9,11) (National Notifiable Diseases Surveillance System(NNDSS)) 5-6 8-9 2013 (1 1 8 4 )1,164 A/H3N2(12)

11

12

7 1 6 30 11 12 3 11%(13) B A/H3N2 2009 H1N12009 7 H1N12010-2011 A/H3N2 12 2009 A/H1N1 2011-2012 BA/H3N2 2012-2013 2010-2011

2009-2013

2008-2009 282009-2010 1,3122010-2011 1,7852011-2012 1,7042012-2013 968 749140155 68 2009

12

13

H1N12008-2009 651-62009-2010 H1N1 180-6 65(13)2010-2011 650-32012-2013 65 50-642009 A/H1N1 0-6 65

(http://www.cdc.gov.tw)//

7 10

10-20 40-50

13

14

B A BA Antigenic drift Antigenic shift

1-2

665 65 1996 2011 7.7% 10.9%

14

15

(Surveillance System)

1.

2. 3. 4. 5. 6.

IC

1999 2000 2004 2007 2011 9

15

16

3 39

( )

+(

)()

( )

1.

()

2.-

(https://ida4.cdc.gov.tw/hospital/)

3.

-(https://ida4.cdc.gov.tw/phb/)

4.

* M38 N O

16

17

()

1.:https://ida4.cdc.gov.tw/phb

2.()

1.:https://ida4.cdc.gov.tw/hospital

2. ()

()

21382

17

18

( )

()()

1.Possible case

2.Probable case

3.Confirmed case

(1)

(2) 14 ()

(3)

( ) (http://nidss.cdc.gov.tw) /

1.() 2. 3. 4.4

18

19

1.()2.

1.()

2.()

1.2.

-

-

21

14()

-

-

**

-

*

*;! 14 )*!

**

19

20

() 1999 3

255

1.

2.

3. () 1.

(1)38

(2)

2. 255 ()

3. 2 2012 8

20

21

4. (1)

(B)

()

()

(A) Transtube

21

22

(2) a. 4 b. 24 c. (*

(3) (real-time PCR*

()() 1. (1) (2)

a. 4 b. 24

(3)(real-time RT- PCR*

2.

1. Virus isolation

2. Real-time

PCR

Real-time PCR() Virus isolation ()





Real-time PCR(+)rapid antigen testvirus isolation(+) 14 21 21 21 H1H3 INF untype,

!Real-time PCR

22

23

( ) (http://cdc.gov.tw)////

( ) !

IC Real-time Outbreak and Disease

SurveillanceRODS1999 9 2004 RODS2006 11 ICD-9-CM1701080%ICD-9-CM

RODS2008ICIC RODS

23

24

RODS(http://nidss.cdc.gov.tw)//!

2009H1N1 H1N1

6

( )

(1) 38

24

25

(2) (3)

() 1. https://ida4.cdc.gov.tw/phb/

2.

( ) 1. 2.

3.

bar-code()

()


25

26

!!https://203.65.72.161/ida2/

2/,!3/A+H1H3

!

!!

!(https://ida4.cdc.gov.tw/phb/)!

!

26

27

2002665 ( ) 1. 38C 2.

()

1.

2.

3.

4.

27

28

5.

6. ( ) (http://cdc.gov.tw)///

28

29

24

24

24

..

1:&

" "

&

!!

29

30

Long term care facilityThe elderly apartmentInstitution for disabilityProtectoryVeterans homePrisonNursing homeDay-care center for mental recovery

( ) 1.

(1) 38 (2)

2.

!1. 38 37.5

2. 3

( ) 1.

(http://iss.cdc.gov.tw)

30

31

2. 24

3. 10

4. ( )

( )

( )

31

32


@

;

- - ) *

; - - < - - /

32

33

() 1.Nasal swab

2.Nasopharyngeal swab 3.Nasal wash fluid

4.Throat swab 5. Transtracheal aspirateBronchoalveolar lavage fluidSputumLung biopsy Post-mortem lung or Tracheal tissue 6. Acute serumConvalescent serum

()

3(Nasopharyngeal aspirate)Throat swab

Immunofluorescence staining

assay, IFA 4 4 48-72-70

33

34

() 1. 10g veal infusion broth 2g bovine albumin fraction V 400 ml

2. 0.8 ml gentamicin sulfate solution (50mg/ml) 3.2 ml amphotericin B (250ug/ml)

3. () 0.8NaCl

()Rapid antigen detection Enzyme immunoassay

Nucleoprotien, NP A B 15-30

()Virus culture 7-14 MDCK(Madin-Darby Canine Kidney cell)Cytopathic Effect, CPEHemagglutination- inhibition, HI () RT-PCR Real-time RT-PCR

7-14 Reverse transcriptase-Polymerase chain reaction (RT-PCR) Realtime RT-PCR

34

35

RT-PCR Realtime RT-PCR(Primer)(RT-PCR)(Realtime RT-PCR)

()

Paired sera104

Neutralization test, NT Hemagglutination inhibition test, HINTHISubtypeStrainHI

Immunofluorescence staining assay, IFA IFA

A B A H1 H3 H5 Anti-mouse IgG FITC conjugate

Virus Culture

MDCK cell(HI)()

35

36

RT-PCR Real-time RT-PCR RT-PCR

RNAPCRReverse transcriptase, RTRNAcDNAPCRHANAMWHO

RT-PCRRT-PCRRT-PCRInternal control

36

37

27X10(2,3,4)A B A B B A (Viral pneumonia)(Bacterial pneumonia)(Encephalitis)(Encephalophy)(Myocarditis)(Pericarditis)(Tansverse myelitis).(Guillain-Barr syndrome)Reye syndrome(2-5) 65() 72

37

38

48 48 65 M2 protein(Neuraminidase)M2 protein Aneuraminidase AB () M2 protein

Amantadine Rimantadine M2 protein (ion channel) M2 protein Amantadine Rimantadine M2 protein M2 protein

Amantadine Rimantadine Amantadine Amantadine CatecholamimeRimantadine

Amantadine 10% 2% Rimantadine A (* () (Neuraminidase)

38

39

Zanamivir (Relenza TM)Oseltamivir (Tamiflu) Peramivir (Rapiacta)A(Hemagglutinin)(Neuraminidase)N-acetylneuraminic acid ( Sialic acid) hemagglutininneuraminidaseSialic acid neuraminidase neuraminidase A BZanamivir 78% 15% 5-15% 2%Oseltamivir oseltamivir carboxylate 75%) 6-10 99%Rapiacta ZanamivirOseltamivir Peramivir 36-48 1-2 0.4% neuraminidase 4% )*!M2 protein A Amantadine Rimantadine

() Neuraminidase Oseltamivir Zanamivir 1-1.5

39

40

() M2 protein M2 proteinAmantadine Rimantadine H3N2 H1N1 100%

() Neuraminidase 1.5% Oseltamivir

M2 protein Neuraminidase M2 protein A B Neuraminidase Oseltamivir Zanamivir A B

M2 protein Neuraminidase

M2 protein Neuraminidase Amantadine Rimantadine Oseltamivir Zanamivir Peramivir Symmetrel, Symadine

Flumadine Tamiflu Relenza Rapiacta

A A A B A B A B 1 1 1-1.5 1-1.5 1 (10%) (2%) (2%) (1.5%) (90-100%) (90-100%) (1.5%)

() Oseltamivir (Tamiflu)

13() 40 1()

40

41

1.(10) 2 5 2.(10) 1 10 () Zanamivir (Relenza)

5()

1. 2(25) 2 5 2. 2(25) 1 10

41

42

-ACIP6185 50

body-mass indext35)

43

A(A/H1N1A/H3N2)B

3(2A1B)4(2A2B)1B2013-2014

11T 2 6570-90%(3-5)3070% (Pneumonia and Influenza, P&I)3040%50~60%80%(2,5,6)76128(15)

universal influenza vaccine

43

44

12 3 9 11 65 661-6

6 3 0.25 ml3 0.5 ml8 1 1

1 2

44

45

Guillain-Barr 1976 2009 H1N1Guillain-Barr

1. 2. 3.

1. 2. 6 3. Guillain-Barr 4.

2-8C

45

46

1. 2. 3.

1.

IC

2. 1

A.

B.

C.

D.

46

47

2(

3LED

4(http://www.cdc.gov.tw)

3. 12 3 9 11 23 10 1

4. H5N1H5N1

H7N9(BMI35)/

5. 1-

2

6.

47

48

1.

2. 3. 4.

/ 1.

2.

3. 4.

1.

2.

1. 2. 3.

1. 2.

3.

4.

1.

2. 3. 4.

48

49

123

1. 2. 3. 4.

1.

2. 1

A. B. C.

D.

2 A. B.

3 A.

B.

49

50

3.

48// 4. 1

!

0! ! ()

1.

2.

3. /

4.

!()

1. !

2. !

3. !

4. !

!()

1. 0!

2. !

3. !

4. ! (

1. !

2. !

3.

50

51

)! () 4. !

() ()

1. !

2. !

3. !

!2

a. (()72)

b. 4848

5. !

(1) 38

51

52

(2) (3)( )

2

()

/

() () 1.

2.

() 1. 2. /

() 48 1. (

)

2.

52

53

3. //

() 1.

(1)

(2) A.

B.

C. 2. /

3. (1) (2) 4.

!!!!!!!!!!!

5. 6. )http://eir.cdc.gov.tw/ *

7. (1)

7 (2)

)http://eir.cdc.gov.tw/ *!

53

54

!!

1. World Health Organization.The world health report 2007 : a safer future : global public health security in the 21st century. World Health Organization; 2007: 45-48.

2. Mandell, GL., Bennett, JE., and Dolin, R. Principles and Practice of Infectious Diseases, 6th eds. Elsevier Inc. 2005: 2060-2078.

3. U.S. Centers for Disease Control and Prevention, National Center for Prevention Services. Prevention and Control of Vaccine-Preventable Diseases: Influenza, 7th eds. U.S. Dept. of Health and Human Services. 2003; 2006: 235-56.

4. Cox N.J. and Subbarao K. Influenza. Lancet; 1999;354: 1277-82. 5. Nicholson K.G., Wood J.M. and Zambon M. Influenza. Lancet; 2003; 362:1733-45. 6. U.S. Centers for Disease Control and Prevention. Prevention and control of

Influenza.Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(RR 10):1-42.

7. Centers for Disease Control and Prevention. Influenza Type A Viruses and Subtypes, 2013. Available at: http://www.cdc.gov/flu/avianflu/influenza-a-virus-subtypes.htm

8. World Health Organization. Influenza. Available athttp://www.who.int/csr/disease/influenza/en/

9. World Health Organization. Weekly Epidemiological Record. Review of the 2012-2013 Winter Influenza Season, Northern Hemisphere; 2013; 88:225-232

10. Sentinel Surveillance. Centre for Health Protection in Hong Kong. Monthly summary tables of influenza virus isolation 2012, 2013. Available at: http://www.chp.gov.hk/en/sentinel/26/44/292.html

11. National Institute of Infectious Disease. Isolation/detection of influenza virus in Japan, week 36/2012-week 11/2013 (as of March 18, 2013). Available at: http://www.nih.go.jp/niid/en/iasr-inf-e.html#graph

12. Australian Government Department of Health and Ageing. Australian Influenza Surveillance Report; 2013 No.4

13. 2002 2004; 20:478-487

14. 2010 2012; 28:113-126

15. Masahiko Katayose et al. The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons. Vaccine 2011;29:1844-49.

54

55

!!

!!

!!

55

56

() / !2/ 213 7 18 2131211842 OEN.2!3/ 213 5 14 2131211574I8O:!4/ 213 4 25 2131211454 !

5/ 213 2 35 2131211173 !6/ 212 21 4 2121212278 !7/ 212 3 8 21212111:9!8/ 211 : 27 21112119:7 !9/ :: : : 1::1112188 OEN.2 !:/ :9 7 2: 1:9111193: I2O2 I2O2 !21/ :8 21 35 1:81112298 3119 22 2!22/!23/ E F !24/!IJW Xftufso!CmpuSU.QDS EOB.QDS IJW BJET DE5=311Dfmmt0nn4!25/ 15.https://ida4.cdc.gov.tw/hospital

()()

!

56

!!!!!!!!!!!!!!!!!!!!!!!!!!

!!!!!!

!

!

!

!

Feve

r!

C

Hea

dach

e

Mya

lgia

M

alai

se

Rhi

norr

hea

Cou

gh

Sore

thro

at

Vom

iting

D

iarr

hea

Ph

aryn

geal

ves

icle

s or u

lcer

s

Para

lysis

Sk

in r

ash

O

ther

s!!!!!!!!

!!!!!!!!

1

38

2

Bar-c

ode

T

hroa

t sw

ab

Nas

opha

ryng

eal s

ecre

tion

or sw

ab

Oth

ers_

____

____

___

//

T

hroa

t sw

ab

Nas

opha

ryng

eal s

ecre

tion

or sw

ab

Oth

ers_

____

____

___

//

____

__

____

__

____

___

VL-

001

!!

!!!

!!!!!!!!::/19/37211/12/12!

57

58

! ! 02-23123456*66908

02-87923311*13568

03-2118800 5497

04-23592525 5701

04-7238595 5930

06-2353535 2653

07-7317123*2578

03-85618255 2090

58

59

!!!

!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

!!!!!!!!!!!!!!!!!!!!!!!!!! 1.34!

!!!!!!!!!!!!!!!!!!!!!!!!! 1.34!

!!!!!

!

!!!!!

!!!!!!!!!!!!!!!!!!!!! 49!!!!!!!!!!!!!!!!!!!!!!!!

1. 2. 3. !

!!!!!

!!!!!!!!!!!!!!!!1.

2. 3.

!!!!!!!!

38!! !!

1. 2. 3. !

!!!!!

1. 2. 3. !

!

!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!)*!

!

!!

59

60

!!!

!!!

!!

!!!!!!

1. !!1(38)

!2!

2. !

!1. !2. !3. !4. !

3837.5!!

!!

!!!!!

!!

60

61

!!

!

!!

!!!!

!!!http://issap.cdc.gov.tw!

!!!!

!!!!!1. !2. !

3. !

4. !

5. !!

!!!

61

62

!!!

!

!

!

!

!!!!!

!!

http://issap.cdc.gov.tw!

!!!

!!!

!

!!!

!!

!!

62

63

!!

!!!!

1. !

2. !

3. !4. !

5. !!

!

!!!

!!

!!!

!!!!!!!!!!!!

63

64

! !!!!

1. !

2.

3. ! 1.

2.

!

1. 2. 3. !

!!!!!

!

1.

2.

!!

1. 2.

3. !!!

1. !

2. !

3. !4. !

!!

!!

1.

2.

3. 4. !

!!!

64

65

!!!!!!

!!!

!

65

!

1.

zM

K-2

cel

l

H29

2 ce

ll

z

200

l

1 m

L

0.45

m

MD

CK

7-10

CPE

3,00

0rpm

15

1 m

L PB

S

21

Ace

tone

Influ

enza

A

Influ

enza

B

mon

oclo

nal

antib

ody

in

dire

ct i

mm

unof

luor

esce

nce

stain

ing

assa

yIF

A

ap

ple

gree

n

2.

Res

pira

tory

viru

ses

follo

w D

AK

O sy

stem

di

rect

IFA

10

l

wet

cha

mbe

r37

15

PBS

PBS

5

3.

Influ

enza

A v

irus H

A ty

ping

by R

T-PC

R m

etho

d

!!

*MK

-2 c

ell

MD

CK

cel

l

CPE!

(+)

(-)

Blin

d pa

ssag

e

66

RN

A

Q

iage

n V

iral R

NA

Min

i Kit

140 l

RN

A

50Pl

AV

E bu

ffer

RN

A

RT

RT

follo

w P

rom

ega

RT

pro

cedu

re

(a).

15

l

RN

A

70

5

RNA

(b).

40

l

RN

A

15

l

5X

buf

fer

5

l

100

mM

dN

TP m

ix

0

.5

l

R

T

1l

Ran

dom

prim

er

1

l

H2O

17

.5

l

PCR

follo

w Q

iage

n PC

R c

ore

kit p

roce

dure

a. P

CR

5X

Q so

lutio

n

10

l

1

0X b

uffe

r

5l

25m

M M

gCl2

4 l

10m

M d

NTP

4

l

R

T

tem

plat

e

2

l

A/H

1 (H

3)-1

10

M

1l

A/H

1 (H

3)-2

10

M

1l

Taq

pol

ymer

ase

0

.5

l

H

2O

22.

5 l

b. P

CR

prog

ram

94

2

94

1

52

2

72

3

72

7

40cy

cles

67

4

FLU

A/B

AB

I

(fio

llow

Taq

Man

one

-ste

p R

T-PC

R m

aste

r mix

reag

ents

proc

edur

e)

Rea

l-tim

e R

T-PC

R

2X M

aste

r mix

buf

fer

1

2.5 L

R

T re

actio

n48

30

FluA

-F p

rimer

10

M

1.0 L

T

aq a

ctiv

atio

n95

10

FluA

-R p

rimer

10M

1.0 L

P

CR

reac

tion

FluB

-F p

rimer

10M

1.0 L

95

1

5

FluB

-R p

rimer

10M

1.0 L

60

1

45 c

ycle

sFl

uA p

robe

5M

0.

5 L

FluB

pro

be

5M

0

.5

LR

NA

enz

yme

mix

0.6

7 L

RN

ase-

free

wat

er

1

.83 L

tem

plat

e

5.

0 L

Roc

he

(Lig

htC

ycle

r 480

RN

A m

aste

r hyd

roly

sis p

robe

s rea

gent

s pro

cedu

re)

RN

ase-

free

wat

er

0.3

L

R

eal-t

ime

RT-

PCR

FluA

-Fpr

imer

10M

1.0 L

R

T re

actio

n63

3!

FluA

-R p

rimer

10M

1.0 L

T

aq a

ctiv

atio

n95

30

FluB

-F p

rimer

10M

1.0 L

PCR

reac

tion

FluB

-R p

rimer

10M

1.0 L

95

1

0

FluA

pro

be

5 M

0.

5 L

58

30!

FluB

pro

be

5 M

0

.5

L

72

3

45 c

ycle

sEn

zym

e m

aste

r mix

7.4

L

Enha

ncer

1

.0

LA

ctiv

ator

1

.3

LR

NA

sam

ple

5

.0

L

68

!!

Prim

er A

/H1

H1-

1: 5

-G

AT

GC

A G

AC

AC

A A

TA T

GT

AG

A G

G-3

Pr

imer

A/H

1 H

1-2:

5-

CN

C T

AC

AG

A G

AC

ATA

AG

C A

TT T

-3

Prim

er A

/H3

H3-

1: 5

-TC

A G

AT

TGA

AG

T G

AC

TA

A T

GC

T-3

Pr

imer

A/H

3 H

3-2:

5-

AA

T TT

T G

AT

GC

C T

GA

AA

C C

GT-

3Fl

uA-F

:5-

AA

G A

CC

AA

T C

CT

GTC

AC

C T

CT

GA

-3

FluA

-R :5

-C

AA

AG

C G

TC T

AC

GC

T G

CA

GTC

C-3

Fl

uB-F

: 5-

GA

G A

CA

CA

A T

TG C

CT A

CC

TG

C T

T -3

Fl

uB-R

: 5

TTC

TTT

CC

C A

CC

GA

A C

CA

AC

-3

FluA

pro

be-F

AM

-5 T

TT G

TG T

TC A

CG

CTC

AC

C G

T 3

-TA

MR

AFl

uB p

robe

-VIC

-5A

GA

AG

A T

GG

AG

A A

GG

CA

A A

GC

AG

A A

CT

AG

C 3-T

AM

RA

FluA

pro

be: 5

FA

M -

TTTG

TGTT

CA

CG

CTC

AC

CG

T 3

BB

QFl

uB p

robe

: 5H

EX-A

GA

AG

ATG

GA

GA

AG

GC

AA

AG

CA

GA

AC

TAG

C

Run

gel

and

read

dat

a

1.5

agar

ose

gel

100

40

Ethi

dium

bro

mid

e

5

5

! ! ! ! ! ! ! !

69

70

!!! / 1

2 ()

3 /

(1)38 (2) (3)

1. 2. /

1 / 2 3 MIS

70

71

()

/

() MIS

()

!

71

/ColorImageDict > /JPEG2000ColorACSImageDict > /JPEG2000ColorImageDict > /AntiAliasGrayImages false /CropGrayImages true /GrayImageMinResolution 300 /GrayImageMinResolutionPolicy /OK /DownsampleGrayImages true /GrayImageDownsampleType /Bicubic /GrayImageResolution 300 /GrayImageDepth -1 /GrayImageMinDownsampleDepth 2 /GrayImageDownsampleThreshold 1.50000 /EncodeGrayImages true /GrayImageFilter /DCTEncode /AutoFilterGrayImages true /GrayImageAutoFilterStrategy /JPEG /GrayACSImageDict > /GrayImageDict > /JPEG2000GrayACSImageDict > /JPEG2000GrayImageDict > /AntiAliasMonoImages false /CropMonoImages true /MonoImageMinResolution 1200 /MonoImageMinResolutionPolicy /OK /DownsampleMonoImages true /MonoImageDownsampleType /Bicubic /MonoImageResolution 1200 /MonoImageDepth -1 /MonoImageDownsampleThreshold 1.50000 /EncodeMonoImages true /MonoImageFilter /CCITTFaxEncode /MonoImageDict > /AllowPSXObjects false /CheckCompliance [ /None ] /PDFX1aCheck false /PDFX3Check false /PDFXCompliantPDFOnly false /PDFXNoTrimBoxError true /PDFXTrimBoxToMediaBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXSetBleedBoxToMediaBox true /PDFXBleedBoxToTrimBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXOutputIntentProfile () /PDFXOutputConditionIdentifier () /PDFXOutputCondition () /PDFXRegistryName () /PDFXTrapped /False

/CreateJDFFile false /Description > /Namespace [ (Adobe) (Common) (1.0) ] /OtherNamespaces [ > /FormElements false /GenerateStructure false /IncludeBookmarks false /IncludeHyperlinks false /IncludeInteractive false /IncludeLayers false /IncludeProfiles false /MultimediaHandling /UseObjectSettings /Namespace [ (Adobe) (CreativeSuite) (2.0) ] /PDFXOutputIntentProfileSelector /DocumentCMYK /PreserveEditing true /UntaggedCMYKHandling /LeaveUntagged /UntaggedRGBHandling /UseDocumentProfile /UseDocumentBleed false >> ]>> setdistillerparams> setpagedevice

流感

Documents